Biotech China 2014

Cancer Biology: Abbott Laboratories

Total Score People Score Events Score
43 31 38
Date Event Presentation Speakers
April 6, 2013 AACR Annual Meetings Expanding the Druggable Genome Chairperson: Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN Stephen Fesik
The Stanley J. Korsmeyer Memorial Symposium: Targeting Cell Death Pathways for Cancer Therapy Chairperson: Anthony G. Letai, Dana-Farber Cancer Institute, Boston, MA Rod Humerickhouse
March 19, 2013 REGEN 2013: Clinical Trials & Reimbursement Baxter Phase III Program in Refractory Angina and Chronis Myocardial Ischemia Adel Nada
May 23, 2012 Biomarkers World Europe 2012 Managing intra-subject variability of human CSF Biomarker levels in clinical studies Jinhe Li
Renal Safety Biomarkers: from the Bench to the Bedside and over the Bumps along the way John Burkhardt
March 26, 2012 World Companion Diagnostics Summit Europe Analysis of Intrasubject Variability in CSF Biomarker Levels from Clinical Trials for Alzheimer’s Disease Jeffrey F. Waring
March 14, 2012 Imaging in Cancer Drug Development Translational imaging to improve probability of success in drug development Yanping Luo
February 20, 2012 Advances and Progress in Drug Design Hit to lead with X-ray crystallography Kenton Longenecker
November 29, 2011 The 7th annual European Antibody Congress is the worldleading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development. Panel session Day 3: Bispecific antibodies and antibody-drug-conjugates Tariq Ghayur
Development of dual-variable domain (DVD) - Ig technology platform: Pre-clinical evaluation of multiple distinct DVD - Ig molecules Tariq Ghayur
May 4, 2010 Biomarker World Congress 2010 Fit-For-Purpose Biomarker Assay Development and Validation* Viswanath Devanarayan
April 30, 2010 Drug Story A Novel Bispecific Antibody Technology Chengbin Wu
April 28, 2010 Kinase Inhibitor Chemistry Rational Mutagenesis to Support Structure-Based Drug Design: MAPKAP Kinase 2 as a Case Study Maria Argiriadi
October 7, 2009 Third Annual Antibodies from Bench to Bedside In Vitro Affinity Maturation of Cardiac Diagnostic Antibodies for Improved Diagnostic Assay Sensitivity Susan Brophy
September 24, 2009 Track 3:Advancing Cancer Therapy : Inaugural Circulating Tumor Cells Title to be Announced Evelyn M. Mckeegan
September 19, 2009 Nature Chemical Biology Symposium 2009: Chemical Biology in Drug Discovery Session chair: Stephen Fesik
August 5, 2009 Drug Safety Strategies to De-Risk Compounds Three Case Studies of Strategic Use of Novel Technologies in Toxicology to De-risk Compounds Eric A Blomme
Conference Chair Opening Remarks Eric A Blomme
August 3, 2009 The Next Wave of Antibody Therapeutics DVD-Ig™: A Novel Dual-Targeting Technology Tariq Ghayur
June 9, 2009 RNAi for Target Identification and Validation Cancer Target Identification and Validation by siRNA Library Screening Xiaoyu Lin
June 9, 2009 Third Annual Cardiotoxicity and Drug Safety Challenges of the Integrative Risk Assessment, the “Heart” of Preclinical Cardiac Safety Evaluations Gary A. Gintant
Chairperson’s Remarks Gary A. Gintant
June 9, 2009 Translating Genomic Knowledge Pharmacogenetics: Finding Value in Early Clinical Trials Anahita Bhathena
June 8, 2009 Tackling RNAi Delivery Pre-Clinical Development of siRNA Delivery in Cancer Therapy Leiming Li
March 9, 2009 Drug Development Latin America Opportunities for Partnering and Innovation in Latin America Sonia M de Morais
January 27, 2009 6th Annual Clinical Trial Performance Metrics Keynote: Real life experience of using metrics in a large pharmaceutical company Michael Meisner
December 1, 2008 European Antibody Congress 2008 Keynote presentation: isotype selection in monoclonal antibody engineering: choosing the right format for success Andrew Goodearl
Panel session: translation of antibody structure-function knowledge in clinical drug candidates Andrew Goodearl
Development of a dual-specific antibody technology: DVD-Ig Chengbin Wu
October 21, 2008 20th EORTC - NCI - AACR Symposium on "Molecular Targets and Cancer Therapeutics" Plenary session 7 Approaches for targeting protein-protein interaction Stephen Fesik
August 21, 2008 The Future of Cancer Diagnostics Early Assessment of Key Challenges in Commercialization of New Biomarkers - Pre-Analytical, Analytical, and Clinical Performance Considerations Gerard J Davis
April 30, 2008 Assessment of Immunogenicity in Clinical Trials Evaluation of Cut Points and Related Characteristics for the Identification and Confirmation of Anti-Drug Antibody Positive Samples Viswanath Devanarayan
April 27, 2008 Phage Display of Antibodies and Peptides DVD-Ig: a Novel Bispecifi c Antibody Technology Chengbin Wu
March 25, 2008 Mastering Medicinal Chemistry Meeting the Challenges of Our Industry - The Role of Technology in a Winning R&D Strategy James B Summers
Medicinal Chemistry Efforts Leading to the Optimization of Histamine H3 Receptor Antagonists Robert J Altenbach
March 25, 2008 PATHWAY ANALYSIS Integration of Novel Technologies in Discovery and Early Development Toxicology Eric A Blomme
March 25, 2008 Preclinical Development Chairperson’s Remarks Eric A Blomme
Integration of Novel Technologies in Discovery and Early Development Toxicology Development Toxicology Eric A Blomme
March 25, 2008 CANCER MOLECULAR MARKERS Chairperson’s Remarks Eric A Blomme
Integration of Novel Technologies in Discovery and Early Development Toxicology Eric A Blomme
November 29, 2007 Cell Signalling and Novel Cancer Therapeutics Bcl-2 family inhibitors for the treatment of cancer Stephen Fesik
November 12, 2007 Well Characterized Biologicals - Continuous Evolution of Chemo- and Bioanalytical Approaches Nov(12 - 14) Stability Indicating Methods and Interpretation of Stability Data for Biotech Products (09:15-12:15) Martin D. Sterman
Stability Indicating Methods and Interpretation of Stability Data for Biotech Products: Multivariate Analysis Applied to Protein Stability Studies (10:15-10:45) Martin D. Sterman
November 5, 2007 Second Annual Biomarkers Europe Nov (05-06) Pre-Conference Tutorial: FIT-FOR-PURPOSE BIOMARKER ASSAY (08:30-12:00) Viswanath Devanarayan
BIOMARKER QUALIFICATION AND VALIDATION (15:45-17:45) Viswanath Devanarayan
BIOMARKER QUALIFICATION AND VALIDATION: Important Considerations in the Discovery and Qualification of Biomarkers for Clinical Use (16:15-16:45) Viswanath Devanarayan
October 17, 2007 Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18) TARGETING PAIN MANAGEMENT (13:55-17:10) Bruce Clapham, Arthur Gomtsyan
TARGETING PAIN MANAGEMENT: Potent and Selective TRPV1 Antagonist for Pain Management (16:40-17:10) Arthur Gomtsyan
October 16, 2007 Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17) New Therapeutics Scopes (10:35-12:40) Yujia Dai
New Therapeutics Scopes: Multitargeted Receptor Tyrosine Kinase Inhibitor ABT-869--Discovery and Clinical Development (11:40-12:10) Yujia Dai
October 16, 2007 Fifth Annual RNAi for Drug Discovery and Therapeutics - Best Practices from the Bench to the Clinic Oct (16-17) RNAi DELIVERY - A THERAPEUTIC CHALLENGE (10:35-12:40) Yu Shen
RNAi DELIVERY - A THERAPEUTIC CHALLENGE: A Robust Positive-readout System for Monitoring siRNA Delivery to Tumors (12:10-12:40) Yu Shen
October 15, 2007 Thirs Annual Quantitative PCR, MicroArrays, And Biologican Validation: Capturing the Complete Biological Story (Oct 15-17) Genetic Variation vs Gene Expression (14:00-19:00) Dimitri Semizarov
Genetic Variation vs Gene Expression: Biomarker Identification Using Comparative Genomic Hybridization (14:35-15:05) Dimitri Semizarov
September 17, 2007 Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19) Pre-Conference Workshops; Biomarker Assay Development and Validation: Part I Tutorial FIT-FOR-PURPOSE BIOMARKER ASSAY DEVELOPMENT AND VALIDATION (08:00-12:00) Viswanath Devanarayan
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.